Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC

Sovran Advisors LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,019 shares of the biopharmaceutical company’s stock after selling 2,600 shares during the quarter. Sovran Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $4,256,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Insigneo Advisory Services LLC boosted its position in Regeneron Pharmaceuticals by 3.0% in the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC increased its holdings in shares of Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 14 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the period. MCF Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares during the period. Finally, Boyd Watterson Asset Management LLC OH boosted its holdings in Regeneron Pharmaceuticals by 1.4% during the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 15 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $3.43 during trading on Friday, reaching $664.52. The company had a trading volume of 581,733 shares, compared to its average volume of 946,751. The firm’s 50-day simple moving average is $645.30 and its 200 day simple moving average is $722.39. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The firm has a market capitalization of $70.25 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 1.46 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the prior year, the business posted $8.22 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $900.00 to $700.00 in a research report on Monday, May 18th. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a research report on Wednesday. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday. Royal Bank Of Canada dropped their target price on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Finally, HSBC cut their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $787.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.